Read this company snapshot
Daily valuation snapshot
Briacell Therapeutics Corp. Common Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $3.91
- Market capitalization (USD)
- $34,016,167.17
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.45
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research BCTX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research BCTX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing BCTX with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $3.91 |
| Market capitalization (USD) | $34,016,167.17 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.45 |
No matching rows. Clear the filter to see all records.
Read BCTX's valuation metrics
Company size
Briacell Therapeutics Corp. Common Shares's recorded market capitalization is $34,016,167.17. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
BCTX's recorded price-to-book ratio is 1.45. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Briacell Therapeutics Corp. Common Shares with Aurora
Use the snapshot above to ask a specific question about BCTX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow BCTX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.